PT97992A - Processo de preparacao de analogos polipeptidicos - Google Patents

Processo de preparacao de analogos polipeptidicos

Info

Publication number
PT97992A
PT97992A PT97992A PT9799291A PT97992A PT 97992 A PT97992 A PT 97992A PT 97992 A PT97992 A PT 97992A PT 9799291 A PT9799291 A PT 9799291A PT 97992 A PT97992 A PT 97992A
Authority
PT
Portugal
Prior art keywords
peptoids
designed
methods
libraries
activity
Prior art date
Application number
PT97992A
Other languages
English (en)
Other versions
PT97992B (pt
Original Assignee
Santi Daniel V
Marlowe Charles K
Paul A Bartlett
Reyna J Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santi Daniel V, Marlowe Charles K, Paul A Bartlett, Reyna J Simon filed Critical Santi Daniel V
Publication of PT97992A publication Critical patent/PT97992A/pt
Publication of PT97992B publication Critical patent/PT97992B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97992A 1990-06-14 1991-06-14 Processo de preparacao de analogos de um patrimonio peptoide com resistencia a protease, e processo para a sintese de uma mistura de polimeros com eles relacionados PT97992B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53833990A 1990-06-14 1990-06-14
US71582391A 1991-06-14 1991-06-14

Publications (2)

Publication Number Publication Date
PT97992A true PT97992A (pt) 1992-04-30
PT97992B PT97992B (pt) 1998-11-30

Family

ID=27065784

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97992A PT97992B (pt) 1990-06-14 1991-06-14 Processo de preparacao de analogos de um patrimonio peptoide com resistencia a protease, e processo para a sintese de uma mistura de polimeros com eles relacionados

Country Status (11)

Country Link
EP (1) EP0535155B1 (pt)
JP (1) JPH06504758A (pt)
AT (1) ATE212641T1 (pt)
AU (2) AU8286891A (pt)
CA (1) CA2085118A1 (pt)
DE (1) DE69132914T2 (pt)
DK (1) DK0535155T3 (pt)
ES (1) ES2167311T3 (pt)
IE (1) IE66205B1 (pt)
PT (1) PT97992B (pt)
WO (1) WO1991019735A1 (pt)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121433A (en) * 1990-07-27 2000-09-19 Isis Pharmaceuticals, Inc. Oligomeric compounds having nitrogen-containing linkages
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
HUT72614A (en) * 1992-09-24 1996-05-28 Chiron Corp Synthesis of n-substituted oligomers
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
WO1994028028A1 (en) * 1993-05-27 1994-12-08 Selectide Corporation Topologically segregated, encoded solid phase libraries
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
EP0788370A4 (en) * 1993-07-09 1998-07-08 Smithkline Beecham Corp CYCLIC, PARTIAL RANDOM PEPTIDE LIBRARIES
US5447916A (en) * 1993-07-30 1995-09-05 Chiron Corporation Peptoid alpha-1 adrenergic receptor ligands
US7034110B2 (en) 1994-01-05 2006-04-25 Arqule, Inc. Method of identifying chemical compounds having selected properties for a particular application
US6828427B1 (en) 1994-01-11 2004-12-07 Isis Pharmaceuticals, Inc. Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same
US6184389B1 (en) 1994-01-11 2001-02-06 Isis Pharmaceuticals, Inc. Combinatorial libraries having aminodiol monomer subunits
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US6207826B1 (en) 1995-03-27 2001-03-27 Isis Pharmaceuticals, Inc. Macrocyclic compounds having nitrogen-containing linkages
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5627210A (en) * 1995-02-06 1997-05-06 Chiron Corporation Branched combinatorial libraries
US6107482A (en) 1995-03-27 2000-08-22 Isis Pharmaceuticals, Inc. Nitrogenous macrocyclic compounds
GB9511474D0 (en) * 1995-06-07 1995-08-02 Ciba Geigy Ag Antiviral peptoid compounds
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
JP2001502293A (ja) * 1996-03-05 2001-02-20 トーレイ パインズ インスティテュート フォー モレキュラー スタディーズ 選択的にｎ―アルキル化されたペプチド模倣的コンビナトリアルライブラリおよびその中の化合物
US6077954A (en) * 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US5990277A (en) * 1996-09-03 1999-11-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
WO1998020437A2 (en) 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998027209A1 (en) * 1996-12-18 1998-06-25 Emory University Polycationic oligomers
US5804386A (en) * 1997-01-15 1998-09-08 Incyte Pharmaceuticals, Inc. Sets of labeled energy transfer fluorescent primers and their use in multi component analysis
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1387390B1 (en) 1997-06-20 2009-02-18 Bio - Rad Laboratories, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US6960457B1 (en) 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
AU757658B2 (en) * 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2323725A1 (en) 1998-03-20 1999-09-23 The Rockefeller University Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
WO1999053295A1 (en) 1998-04-14 1999-10-21 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
WO2000073799A1 (en) 1999-06-01 2000-12-07 Caliper Technologies Corp. Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
EP1251904A1 (en) 2000-02-03 2002-10-30 The Regents of the University of California Assays for the detection of agents that affect cognition
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
WO2001065462A2 (en) 2000-02-29 2001-09-07 3-Dimensional Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US7039621B2 (en) 2000-03-22 2006-05-02 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method, and computer program product for representing object relationships in a multidimensional space
WO2001075790A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for representing object relationships in a multidimensional space
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE500838T1 (de) 2000-09-08 2011-03-15 Amylin Pharmaceuticals Inc ßPSEUDOß-NATIVE CHEMISCHE LIGATION
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
EP1404867B1 (en) 2000-12-23 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Oligonucleotide transfection screening method
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7054757B2 (en) 2001-01-29 2006-05-30 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Method, system, and computer program product for analyzing combinatorial libraries
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
WO2002095356A2 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
EP2003451B1 (en) 2001-06-26 2012-05-30 Senomyx, Inc. T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
US7413870B2 (en) 2001-08-01 2008-08-19 Rigel Pharmaceuticals, Incorporated SAK: modulation of cellular proliferation for treatment of cancer
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7091331B2 (en) 2002-03-04 2006-08-15 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides encoding baboon TAFI
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
MXPA05007615A (es) 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
WO2004098764A2 (en) 2003-04-30 2004-11-18 Aurora Discovery, Inc. Multi-well plate providing a high-density storage and assay platform
KR101291787B1 (ko) 2003-05-30 2013-08-07 어젠시스 인코포레이티드 전립선 줄기 세포 항원 (ｐｓｃａ) 변이체 및 그의서브서열
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
JP2007512227A (ja) 2003-08-06 2007-05-17 セノミックス、インコーポレイテッド Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
JP4746552B2 (ja) 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
PL1734996T3 (pl) 2004-04-02 2013-09-30 Univ California Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
EP2428522A1 (en) 2004-05-28 2012-03-14 Agensys, Inc. Antibodies that bind to PSCA proteins for diagnosis of cancer
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
PT1786430E (pt) 2004-08-20 2013-06-04 Buck Inst For Age Res Pequenas moléculas que substituam ou agonizam a função p53
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
BRPI0609655A2 (pt) 2005-03-31 2010-03-16 Agensys Inc anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
NZ565172A (en) 2005-07-19 2012-12-21 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
EP1931695B1 (en) * 2005-09-09 2013-04-10 Novartis AG Prion-specific peptoid reagents
US7781209B2 (en) 2005-09-25 2010-08-24 Multispan, Inc. GPCR-expressing cell lines
MX2007015931A (es) 2005-10-20 2008-04-22 Senomyx Inc Receptores de sabor dulce-umami y umami-dulce humanos quimericos.
RU2008115455A (ru) 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2007227195A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
EP3235811B1 (en) 2006-04-21 2018-07-25 Senomyx, Inc. Process of preparing oxalamides
JP4785919B2 (ja) 2006-05-02 2011-10-05 学校法人帝京大学 グルタチオン増加物質のスクリーニング方法
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
DE602006012460D1 (de) 2006-06-07 2010-04-08 Nutrinova Gmbh Verfahren zum Screening von Substanzen die die Aktivität von Gpcrs modulieren
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
DE102006039615A1 (de) * 2006-08-24 2008-03-13 Leibniz-Institut Für Pflanzenbiochemie Esterelongationsverfahren zum sequenzgesteuerten Aufbau alternierender Peptid-Peptoid-Polymere (Peptid-Peptoid-Polymere)
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
PT2062049E (pt) 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
AU2008209473B2 (en) 2007-01-22 2012-10-25 Orthotrophix, Inc. A peptide composition and a method of promoting cartilage formation
KR20100031528A (ko) 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
ES2477294T3 (es) 2007-08-13 2014-07-16 Baxter International Inc Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
ES2545121T3 (es) 2007-08-21 2015-09-08 Senomyx, Inc. Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos
WO2009045377A2 (en) 2007-10-01 2009-04-09 Redpoint Bio Corporation A non-desensitizing mutant of the transient receptor potential trpm5 ion channel
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
AU2009239491B2 (en) 2008-04-21 2014-07-17 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
WO2009139922A2 (en) * 2008-05-16 2009-11-19 New York University School Of Medicine Peptoid compositions and methods of using the same
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
ES2642793T3 (es) 2008-11-06 2017-11-20 University Of Miami Papel de uPAR soluble en la patogenia de enfermedad renal proteinúrica
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
ES2489040T3 (es) 2008-12-03 2014-09-01 The Scripps Research Institute Cultivos de células madre
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
MX2011005912A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
KR101829469B1 (ko) 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
US20100233172A1 (en) 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
JP6093110B2 (ja) 2008-12-17 2017-03-08 ザ スクリプス リサーチ インスティテュート 幹細胞の作製と維持
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN102388064A (zh) 2009-03-27 2012-03-21 高裘企业公司 用于筛选与使用拮抗孢子-表面交互作用的化合物的组合物与方法
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2427204B1 (en) 2009-05-06 2017-04-05 Janssen Biotech, Inc. Melanocortin receptor binding conjugates
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN102612560B (zh) 2009-06-16 2017-10-17 库尔纳公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
JP6128848B2 (ja) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
CA2770104C (en) 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
CN102576022B (zh) 2009-08-14 2016-06-15 加利福尼亚大学董事会 诊断和治疗自闭症的方法
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
US20120189578A1 (en) 2009-08-24 2012-07-26 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
KR101892760B1 (ko) 2009-08-25 2018-08-28 큐알엔에이, 인크. ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
KR101802540B1 (ko) 2009-09-25 2017-11-28 큐알엔에이, 인크. Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
CA2781290A1 (en) 2009-11-20 2011-05-26 Lynn K. Gordon Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
KR101838305B1 (ko) 2009-12-29 2018-03-13 큐알엔에이, 인크. ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
EP2521784B1 (en) 2010-01-04 2017-12-06 CuRNA, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US9216189B2 (en) 2010-01-25 2015-12-22 Icahn School Of Medicine At Mount Sinai Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
CN102782135A (zh) 2010-01-25 2012-11-14 库尔纳公司 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
US20130137584A1 (en) 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CA2795145C (en) 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
RU2620978C2 (ru) 2010-05-26 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
EP2400304A1 (en) 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
KR101914309B1 (ko) 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
NO2593547T3 (pt) 2010-07-14 2018-04-14
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
JP6049623B2 (ja) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
EP2643484A4 (en) 2010-11-22 2014-04-16 Univ California METHOD OF IDENTIFYING AN RNA TRANSCRIPTION OF CELLULAR ORIGIN
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
EP2738255B1 (en) 2011-07-29 2016-11-23 Tokushima University Erap1-derived peptide and use thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
WO2013063492A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
DK2790687T3 (en) 2011-12-16 2018-11-19 Poseida Therapeutics Inc TRPC4 MODULATORS FOR USE IN TREATMENT OR PREVENTION OF Pain
HK1205952A1 (en) 2012-02-16 2015-12-31 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
WO2013138456A1 (en) 2012-03-14 2013-09-19 University Of Central Florida Research Foundation, Inc. Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
EP2825648B1 (en) 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN104379563B (zh) 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
HK1209430A1 (en) 2012-04-24 2016-04-01 迈阿密大学 Perforin 2 defense against invasive and multidrug resistant pathogens
WO2013184645A2 (en) 2012-06-04 2013-12-12 The Scripps Research Institute Novel phenyl glyoxal probes
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
EP2912194B1 (en) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
US20140288097A1 (en) 2013-02-07 2014-09-25 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CA2909721A1 (en) 2013-04-19 2014-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lone star virus
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
WO2015057461A2 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
WO2015089338A2 (en) 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
KR102629269B1 (ko) 2015-02-27 2024-01-24 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
US10851423B2 (en) 2015-06-22 2020-12-01 Proteovista Llc SNP arrays
WO2016207313A1 (en) 2015-06-24 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for detecting protein-protein interactions
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3555077B1 (en) 2016-12-15 2023-04-19 The Regents of The University of California Compositions and methods for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11771703B2 (en) 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
CA3057999A1 (en) 2017-04-04 2018-10-11 Loma Linda University Biologic for the treatment of cancer
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
WO2019046791A1 (en) 2017-09-01 2019-03-07 The Johns Hopkins University TARGETED EPIGENETIC THERAPY FOR AERIAL CONDITION OF AERTICAL HERITATION
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
US20210247386A1 (en) 2018-04-26 2021-08-12 Technion Research & Development Foundation Limited A device and method for determining cell indentation activity
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
EP4247427A4 (en) 2020-11-19 2025-04-09 The Chinese University of Hong Kong Assessing risk for colorectal adenoma recurrence by noninvasive means
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234185A (en) * 1962-04-26 1966-02-08 Coastal Interchemical Company Process for increasing the molecular weight of amine-containing polymers
US4496542A (en) * 1981-03-30 1985-01-29 Usv Pharmaceutical Corporation N-substituted-amido-amino acids
EP0085488B1 (en) * 1982-01-23 1990-03-28 Ajinomoto Co., Inc. Amino acid derivatives and antihypertensive drugs containing them
US4444759A (en) * 1982-07-26 1984-04-24 The Salk Institute For Biological Studies GnRH Antagonists II
US4746490A (en) * 1983-09-22 1988-05-24 Saneii Hossain H Solid phase peptide synthesizer
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
FR2582655B1 (fr) * 1985-06-03 1988-12-23 Centre Nat Rech Scient Multi-synthetiseur de peptides semi-automatique en phase solide
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties

Also Published As

Publication number Publication date
IE912021A1 (en) 1991-12-18
AU8286891A (en) 1992-01-07
PT97992B (pt) 1998-11-30
ATE212641T1 (de) 2002-02-15
EP0535155A4 (en) 1994-08-17
DE69132914D1 (de) 2002-03-14
IE66205B1 (en) 1995-12-13
WO1991019735A1 (en) 1991-12-26
CA2085118A1 (en) 1991-12-15
DE69132914T2 (de) 2002-09-19
AU3296495A (en) 1996-03-07
JPH06504758A (ja) 1994-06-02
ES2167311T3 (es) 2002-05-16
EP0535155B1 (en) 2002-01-30
DK0535155T3 (da) 2002-02-25
EP0535155A1 (en) 1993-04-07
AU683184B2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
DK0535155T3 (da) Samlinger af modificerede peptider med proteaseresistens
DE69213272T2 (de) Zusammensetzung zum Induzieren einer humoralen Anergie gegen ein Immunogen
DE68912268T2 (de) Elastomere polypeptide als vaskulare prothesematerialien.
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
GR1001011B (el) Θεραπευτικος παραγων.
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
DE69736976D1 (de) Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
SK283083B6 (sk) Polyetylénglykolový derivát polypeptidu, spôsob pripájania polyetylénglykolu na polypeptid a homogénny prípravok monopegylovaného BDNF a NT-3
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
DK0473724T3 (da) Et humant cytokin, interleukin-9
EP0651818A4 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding.
JP2001506609A (ja) 生理活性の増加した多量体エリスロポエチン
ATE242813T1 (de) Rekombinante durch gallensalz aktivierte lipasen
WO1994020521A1 (de) Verfahren zur synthese und selektionierung von sequenzen aus kovalent verbundenen bausteinen
SE8704158L (sv) Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
ATE152771T1 (de) Methode zur herstellung und prüfung von verwendbaren peptiden
DE69218193D1 (de) Verfahren zur Synthese von Peptiden, Derivate von Aminosäuren zur Verwendung bei dem obengenannten Verfahren und Methoden zu deren Herstellung.
DE69922245T2 (de) Biologisch wirksame konjugate mit einem reporterrest und verfahren zu dessen nachweis
DE69737202T2 (de) Thrombolytische substanzen mit antithrombotische aktivität
DE19525784A1 (de) Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE68914397D1 (de) Menschliches Lymphotoxin.
CA2050941A1 (en) Antibody to smooth muscle myosin heavy chains
ATE260339T1 (de) Antikörper gegen menschliches restrictin
FR2656307B1 (fr) Derives du (n-methyl-n-alcoyl)amino-3 methoxymethylene-2 propane 1-ol, ainsi que leur procede de preparation.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19911122

FC3A Refusal

Effective date: 19930922

FG3A Patent granted, date of granting

Effective date: 19980824

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000229